Cargando…

Analysis of strategy and efficacy clinical treatments of Kümmell disease: a cohort study

BACKGROUND: Most clinical reports on the surgical treatment of kümmell disease lack consistency between classification and treatment protocol. In this study, we investigate the most appropriate and effective clinical treatment strategies according to the characteristics of different types of Kümmell...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Weixing, Ding, Weiguo, Xu, Xinwei, Sheng, Hongfeng, Zhu, Jiafu, Xin, Long, Xu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577779/
https://www.ncbi.nlm.nih.gov/pubmed/36267721
http://dx.doi.org/10.21037/atm-22-3801
_version_ 1784811835492401152
author Xu, Weixing
Ding, Weiguo
Xu, Xinwei
Sheng, Hongfeng
Zhu, Jiafu
Xin, Long
Xu, Bin
author_facet Xu, Weixing
Ding, Weiguo
Xu, Xinwei
Sheng, Hongfeng
Zhu, Jiafu
Xin, Long
Xu, Bin
author_sort Xu, Weixing
collection PubMed
description BACKGROUND: Most clinical reports on the surgical treatment of kümmell disease lack consistency between classification and treatment protocol. In this study, we investigate the most appropriate and effective clinical treatment strategies according to the characteristics of different types of Kümmell disease. METHODS: A retrospective analysis was performed of 48 patients with Kümmell disease treated in Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China for which complete follow-up data were available. All cases were classified into six types: type I, vertebral body height loss less than 20% and no intervertebral disc degeneration from adjacent segments; type II, vertebral body height loss more than 20% and accompanied by degeneration or mild instability of intervertebral discs at adjacent segments; type III, posterior vertebral cortical rupture and dural sac compression, and some accompanied by spinal cord nerve injury. Type III includes type IIIA (recoverable stable type), type IIIB (recoverable unstable type), type IIIC (spinal stenosis type), and type IIID (kyphosis type). Methods of surgery: patients of types I, II, and IIIA were treated with percutaneous vertebroplasty (PVP) or percutaneous kyphoplasty (PKP), type IIIB were treated with posterior fixation and fusion, type IIIC were treated with posterior decompression and fixation fusion, and type IIID were treated with posterior osteotomy, orthopedic fixation, and fusion. All patients were followed up for 10–44 months (mean, 20.5±4.5 months). The preoperative and postoperative visual analog scale (VAS) scores, Owestry disability index (ODI) scores, secondary height loss and kyphosis, and neurological improvement were followed up and statistically analyzed. RESULTS: The VAS and ODI scores of all cases were improved compared with those pre-surgery (P<0.05). A total of 8 cases showed loss of vertebral height or secondary kyphosis. The American Spinal Injury Association (ASIA) grades of patients with neural impairment were all improved at the last follow-up. CONCLUSIONS: According to the characteristics of different types of Kümmell disease, appropriate clinical treatment strategies can achieve satisfactory curative effects and reduce the occurrence of complications. This study is only a retrospective study, lacks a control group, and the sample size is small. Therefore, it has limitations and does not provide guidance.
format Online
Article
Text
id pubmed-9577779
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-95777792022-10-19 Analysis of strategy and efficacy clinical treatments of Kümmell disease: a cohort study Xu, Weixing Ding, Weiguo Xu, Xinwei Sheng, Hongfeng Zhu, Jiafu Xin, Long Xu, Bin Ann Transl Med Original Article BACKGROUND: Most clinical reports on the surgical treatment of kümmell disease lack consistency between classification and treatment protocol. In this study, we investigate the most appropriate and effective clinical treatment strategies according to the characteristics of different types of Kümmell disease. METHODS: A retrospective analysis was performed of 48 patients with Kümmell disease treated in Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China for which complete follow-up data were available. All cases were classified into six types: type I, vertebral body height loss less than 20% and no intervertebral disc degeneration from adjacent segments; type II, vertebral body height loss more than 20% and accompanied by degeneration or mild instability of intervertebral discs at adjacent segments; type III, posterior vertebral cortical rupture and dural sac compression, and some accompanied by spinal cord nerve injury. Type III includes type IIIA (recoverable stable type), type IIIB (recoverable unstable type), type IIIC (spinal stenosis type), and type IIID (kyphosis type). Methods of surgery: patients of types I, II, and IIIA were treated with percutaneous vertebroplasty (PVP) or percutaneous kyphoplasty (PKP), type IIIB were treated with posterior fixation and fusion, type IIIC were treated with posterior decompression and fixation fusion, and type IIID were treated with posterior osteotomy, orthopedic fixation, and fusion. All patients were followed up for 10–44 months (mean, 20.5±4.5 months). The preoperative and postoperative visual analog scale (VAS) scores, Owestry disability index (ODI) scores, secondary height loss and kyphosis, and neurological improvement were followed up and statistically analyzed. RESULTS: The VAS and ODI scores of all cases were improved compared with those pre-surgery (P<0.05). A total of 8 cases showed loss of vertebral height or secondary kyphosis. The American Spinal Injury Association (ASIA) grades of patients with neural impairment were all improved at the last follow-up. CONCLUSIONS: According to the characteristics of different types of Kümmell disease, appropriate clinical treatment strategies can achieve satisfactory curative effects and reduce the occurrence of complications. This study is only a retrospective study, lacks a control group, and the sample size is small. Therefore, it has limitations and does not provide guidance. AME Publishing Company 2022-09 /pmc/articles/PMC9577779/ /pubmed/36267721 http://dx.doi.org/10.21037/atm-22-3801 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Xu, Weixing
Ding, Weiguo
Xu, Xinwei
Sheng, Hongfeng
Zhu, Jiafu
Xin, Long
Xu, Bin
Analysis of strategy and efficacy clinical treatments of Kümmell disease: a cohort study
title Analysis of strategy and efficacy clinical treatments of Kümmell disease: a cohort study
title_full Analysis of strategy and efficacy clinical treatments of Kümmell disease: a cohort study
title_fullStr Analysis of strategy and efficacy clinical treatments of Kümmell disease: a cohort study
title_full_unstemmed Analysis of strategy and efficacy clinical treatments of Kümmell disease: a cohort study
title_short Analysis of strategy and efficacy clinical treatments of Kümmell disease: a cohort study
title_sort analysis of strategy and efficacy clinical treatments of kümmell disease: a cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577779/
https://www.ncbi.nlm.nih.gov/pubmed/36267721
http://dx.doi.org/10.21037/atm-22-3801
work_keys_str_mv AT xuweixing analysisofstrategyandefficacyclinicaltreatmentsofkummelldiseaseacohortstudy
AT dingweiguo analysisofstrategyandefficacyclinicaltreatmentsofkummelldiseaseacohortstudy
AT xuxinwei analysisofstrategyandefficacyclinicaltreatmentsofkummelldiseaseacohortstudy
AT shenghongfeng analysisofstrategyandefficacyclinicaltreatmentsofkummelldiseaseacohortstudy
AT zhujiafu analysisofstrategyandefficacyclinicaltreatmentsofkummelldiseaseacohortstudy
AT xinlong analysisofstrategyandefficacyclinicaltreatmentsofkummelldiseaseacohortstudy
AT xubin analysisofstrategyandefficacyclinicaltreatmentsofkummelldiseaseacohortstudy